Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection

Abstract This study aimed to determine the incidence and characteristics of active tuberculosis (TB) in patients treated with tumor necrosis factor (TNF) antagonists according to baseline latent tuberculosis infection (LTBI). Data were retrospectively obtained from 702 patients aged ≥20 years treate...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Eun Hye Lee, Young Ae Kang, Ah Young Leem, Moo Suk Park, Young Sam Kim, Se Kyu Kim, Joon Chang, Song Yee Kim
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/13baadf8b8784380a6a786f45a8bb5bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:13baadf8b8784380a6a786f45a8bb5bc
record_format	dspace
spelling	oai:doaj.org-article:13baadf8b8784380a6a786f45a8bb5bc2021-12-02T11:53:09ZActive Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection10.1038/s41598-017-06899-12045-2322https://doaj.org/article/13baadf8b8784380a6a786f45a8bb5bc2017-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-06899-1https://doaj.org/toc/2045-2322Abstract This study aimed to determine the incidence and characteristics of active tuberculosis (TB) in patients treated with tumor necrosis factor (TNF) antagonists according to baseline latent tuberculosis infection (LTBI). Data were retrospectively obtained from 702 patients aged ≥20 years treated with TNF antagonists between November 2005 and June 2016 at Severance Hospital, a tertiary referral hospital in Seoul, South Korea. The interferon-gamma release assay (IGRA) with or without a tuberculin skin test (TST) was used to diagnose LTBI. Of the total of 702 patients, LTBI was diagnosed in 255 (36.3%) patients. 23.9% (168/702) had positive IGRA results, and 32.2% (165/512) had positive TST results. Five patients developed active TB after LTBI treatment, and 6 developed TB despite baseline negative LTBI results. After adjustment for age and sex, the standardized TB incidence ratio was 6.01 (95% CI 1.94–14.04) in the LTBI group and 5.14 (95% CI 1.88–11.18) in the baseline negative LTBI group. Clinicians should be aware of the risk of active TB in patients treated with TNF antagonists despite baseline negative LTBI screening results. Regular monitoring and serial tests should be considered during long-term TNF antagonist therapy, especially in intermediate to high TB burden country.Eun Hye LeeYoung Ae KangAh Young LeemMoo Suk ParkYoung Sam KimSe Kyu KimJoon ChangSong Yee KimNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Eun Hye Lee Young Ae Kang Ah Young Leem Moo Suk Park Young Sam Kim Se Kyu Kim Joon Chang Song Yee Kim Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection
description	Abstract This study aimed to determine the incidence and characteristics of active tuberculosis (TB) in patients treated with tumor necrosis factor (TNF) antagonists according to baseline latent tuberculosis infection (LTBI). Data were retrospectively obtained from 702 patients aged ≥20 years treated with TNF antagonists between November 2005 and June 2016 at Severance Hospital, a tertiary referral hospital in Seoul, South Korea. The interferon-gamma release assay (IGRA) with or without a tuberculin skin test (TST) was used to diagnose LTBI. Of the total of 702 patients, LTBI was diagnosed in 255 (36.3%) patients. 23.9% (168/702) had positive IGRA results, and 32.2% (165/512) had positive TST results. Five patients developed active TB after LTBI treatment, and 6 developed TB despite baseline negative LTBI results. After adjustment for age and sex, the standardized TB incidence ratio was 6.01 (95% CI 1.94–14.04) in the LTBI group and 5.14 (95% CI 1.88–11.18) in the baseline negative LTBI group. Clinicians should be aware of the risk of active TB in patients treated with TNF antagonists despite baseline negative LTBI screening results. Regular monitoring and serial tests should be considered during long-term TNF antagonist therapy, especially in intermediate to high TB burden country.
format	article
author	Eun Hye Lee Young Ae Kang Ah Young Leem Moo Suk Park Young Sam Kim Se Kyu Kim Joon Chang Song Yee Kim
author_facet	Eun Hye Lee Young Ae Kang Ah Young Leem Moo Suk Park Young Sam Kim Se Kyu Kim Joon Chang Song Yee Kim
author_sort	Eun Hye Lee
title	Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection
title_short	Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection
title_full	Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection
title_fullStr	Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection
title_full_unstemmed	Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection
title_sort	active tuberculosis incidence and characteristics in patients treated with tumor necrosis factor antagonists according to latent tuberculosis infection
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/13baadf8b8784380a6a786f45a8bb5bc
work_keys_str_mv	AT eunhyelee activetuberculosisincidenceandcharacteristicsinpatientstreatedwithtumornecrosisfactorantagonistsaccordingtolatenttuberculosisinfection AT youngaekang activetuberculosisincidenceandcharacteristicsinpatientstreatedwithtumornecrosisfactorantagonistsaccordingtolatenttuberculosisinfection AT ahyoungleem activetuberculosisincidenceandcharacteristicsinpatientstreatedwithtumornecrosisfactorantagonistsaccordingtolatenttuberculosisinfection AT moosukpark activetuberculosisincidenceandcharacteristicsinpatientstreatedwithtumornecrosisfactorantagonistsaccordingtolatenttuberculosisinfection AT youngsamkim activetuberculosisincidenceandcharacteristicsinpatientstreatedwithtumornecrosisfactorantagonistsaccordingtolatenttuberculosisinfection AT sekyukim activetuberculosisincidenceandcharacteristicsinpatientstreatedwithtumornecrosisfactorantagonistsaccordingtolatenttuberculosisinfection AT joonchang activetuberculosisincidenceandcharacteristicsinpatientstreatedwithtumornecrosisfactorantagonistsaccordingtolatenttuberculosisinfection AT songyeekim activetuberculosisincidenceandcharacteristicsinpatientstreatedwithtumornecrosisfactorantagonistsaccordingtolatenttuberculosisinfection
_version_	1718394851282649088

Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection

Ejemplares similares